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Poor adherence (compliance) to antihypertensive medica-
tions is a major contributor to morbidity and mortality in
patients with hypertension. Estimates in the literature of
the extent of poor adherence in patients with hypertension
vary between around 20% and 80%, so it is difﬁcult to be sure
of the proportion of patients affected. Good adherence to
antihypertensive medications is important. In addition to
achieving better blood pressure control and thus reducing
adverse hypertension-related outcomes, good adherence
prevents unnecessary treatment escalation, additional
appointments, investigations for secondary causes and even
potentially invasive interventions.
In a recent issue of BJCP, Avataneo et al. report a study
that used therapeutic drug monitoring to deﬁne antihyper-
tensive medication adherence proﬁles in patients with
suspected resistant hypertension referred to a hypertension
unit in Turin, Italy [1]. A liquid chromatography–tandem
mass spectrometry approach was used to quantify a panel of
ten different antihypertensive drugs in human plasma. Of
the 50 patients considered to have apparent resistant hyper-
tension who underwent therapeutic drug monitoring, 24%
were found to be only partly adherent and 18% totally
non-adherent to the antihypertensive medications they had
been prescribed. The team also attempted to identify
predictors of poor adherence and look at associations
between self-reported adherence (albeit using a nonvalidated
questionnaire), physician opinion of adherence and results of
the therapeutic drug monitoring. No association was found
with self-reported adherence, while physicians were often
able to identify non-adherence. Interestingly, all nine
patients found to be totally non-adherent according to results
of therapeutic drug monitoring self-reported that they were
fully adherent. Factors found to be associated with non-
adherence included higher blood pressures, higher heart rate,
previous coronary artery disease or stroke and previous inva-
sive treatments including renal denervation and baroreceptor
stimulation. The authors concluded that there was a high
prevalence of poor adherence in this patient group and
expressed the need for caution in use of invasive treatments
in patients with resistant hypertension without ﬁrst
addressing adherence. They suggested that there was a need
for validation of the use of therapeutic drug monitoring in a
wider cohort of patients to inform whether it should become
routine clinical practice.
This was a relatively small study andmeasured a relatively
small panel of antihypertensive drugs, but it adds to our
knowledge of the extent of non-adherence in this important
group of patients with resistant hypertension and some of
the possible predictors of non-adherence in such patients.
Resistant hypertension is a difﬁcult problem, and while
recent clinical trials such as PATHWAY-2 have highlighted
effective treatment options in this scenario [2], identifying
which patients have true resistant hypertension is important
before additional therapies or other interventions are
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introduced, and one of the key things to exclude is non-
adherence to medications.
There have been previous studies also describing the
measurement of drugs or biomarkers in urine or blood of pa-
tients with hypertension. These more objective methods of
assessing adherence have become more popular and widely
available in recent years. For example, in 2014, Tomaszewski
et al. published a study that used high-performance liquid
chromatography–tandem mass spectrometry urine analysis
to screen for the 40 most commonly prescribed medications
or their metabolites in spot urine samples of 208 hyperten-
sive patients attending a specialist hypertension centre in
Leicester, United Kingdom [3]. Twenty-ﬁve per cent of these
patients were found to be totally or partially non-adherent
to antihypertensive treatment. The highest prevalence of
poor adherence was among ‘follow-up’ patients with inade-
quate blood pressure control and patients who at the time
had been referred for consideration of renal denervation ther-
apy. Another study using similar urine analysis techniques
highlighted that in patients from the United Kingdom and
the Czech Republic being screened for adherence due to
suspicion of non-adherence, the more antihypertensive
medications patients were prescribed, the more likely they
were to be non-adherent. In that study, nearly 80% of the
patients in the United Kingdom who were prescribed six or
more antihypertensive medications were found to be non-
adherent [4]. A Dutch post hoc analysis of nearly 100 patients
with apparent resistant hypertension previously included in
the SYMPATHY renal denervation randomized-controlled
trial showed that, on testing of stored blood samples using
liquid chromatography–tandem mass spectrometry, 68% of
the patients were non-adherent [5]. Patients and clinicians
were unaware that there would be an assessment of
adherence at the time these samples were collected as ethical
approval to perform this analysis on the stored samples was
obtained retrospectively.
Measurement of drugs or biomarkers is just one way of
assessing adherence. Different methods are available depend-
ing on the setting and the resource available. These alterna-
tives range on a spectrum from the less accurate but
relatively simple methods of asking the patient, patient
diaries, basic adherence questionnaires and pill counts to
the more accurate but more invasive or expensive methods
of review of prescription or dispensing records, electronic
monitoring devices such as ‘smart containers’ or directly
observed therapy [6]. Measurement of drug or biomarkers in
urine or plasma would be classed as one of the more invasive
and expensive but objective methods.
Adherence to medication is a general marker of good
health behaviour. A 2006 meta-analysis noted that good ad-
herence to placebo was associated with a 44% lower mortality
[7]. When we consider non-adherence, we often think about
patients ‘forgetting’ to take their medication – so-called
‘unintentional non-adherence’. However, ‘intentional non-
adherence’ is probably much more common than we think.
Some patients have a frank discussion with their clinician
about the extent of their non-adherence and the reasons for
it. However, we know that there are probably many more
patients who choose not to disclose this or are perhaps not in-
vited or encouraged enough to discuss it openly. There are
also some patients who show ‘white-coat adherence’, starting
to take their medications regularly just before each contact
with a health care professional but taking them less regularly
at other times. At the other extreme, ‘over-adherence’ can
also be a problem with patients escalating doses higher than
those recommended leading to adverse effects or taking addi-
tional medications not currently prescribed with the possibil-
ity of interactions. There is also the issue of ‘pathological
adherence’, when patients persist with taking a medication
that is causing them signiﬁcant side effects without seeking
help until their next routine follow-up appointment.
Identifying non-adherence is a good thing. It puts all the
cards on the table and opens up an honest discussion
between the patient and the clinician so that they may se-
lect an appropriate and realistic management plan that is
acceptable to both. Educating the patient about hyperten-
sion and the beneﬁts of treatment is important, as is build-
ing a good clinician–patient relationship. Ideally, we
should ask every patient about adherence at every appoint-
ment. However, in the authors’ opinions and clinical experi-
ence, and based on the literature around adherence [8],
there are a few ‘warning signals’ that should prompt a more
detailed consideration of adherence (Table 1). While at-
tempts to measure and address adherence with patients’
co-operation are important, we must also respect patients’
autonomy to make their own decisions about whether to
take medications or not.
It is clear from the Avataneo et al. study and others that
patient self-reporting of adherence is unreliable. In addition,
clinicians cannot always tell when poor adherence is a
contributing factor to resistant hypertension. Therefore,
more objective measures of adherence that can be applied
during a routine consultation are welcome. In clinical care,
the patient should of course be informed and give their
consent to have any invasive measurement of adherence
performed as part of the consultation. Several studies have
Table 1
‘Warning signals’ that should prompt a detailed consideration of
adherence to antihypertensive medication
Patient expresses a lack of belief in beneﬁts of antihypertensive
treatment
Patient expresses concerns about adverse effects of medications
Patient expresses that they are tired of taking medications
Patient expresses a fear of lifelong treatment
Poor understanding of hypertension and the beneﬁts of treatment
Unexpected increase in blood pressure
Inadequate response to treatment or ‘resistant hypertension’
Complex treatment regimen or multiple co-morbidities
Poor attendance at planned review appointments
Communication difﬁculties
Previous unsatisfactory clinician encounters
Depression or other psychiatric illness
Signiﬁcant competing priorities, e.g. caring responsibilities for other
family members, ﬁnancial issues (in some health care settings)
Poor social or family support network
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now shown that techniques such as that described in the
Avataneo et al. study can be applied effectively in various
populations of patients with hypertension. In our opinion,
these measurements are very likely to be cost-effective in
the longer term, given the potential avoidance of years of
unnecessary or unhelpful appointments and additional
interventions once non-adherence is revealed and can be
addressed. As availability of these measurement techniques
improves, health services should embrace their use, at least
in selected patients such as those with apparent resistant
hypertension. Deﬁnitively identifying patients in whom
adherence is an issue is the ﬁrst step to improving their care
in the future. The next steps involve successfully addressing
non-adherence once identiﬁed while continuing to respect
patients’ autonomy. Already, behavioural interventions such
as motivational interviewing show some promise in this area
[9]. Further research into how best to act upon the results of
drugmonitoring to improve adherence and patient outcomes
and how these efforts can effectively be incorporated into
clinical care for patients with hypertension is required.
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